Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study

• Published in: Neurourology and urodynamics Vol. 36; no. 3; pp. 734 - 739
• Main Authors: Peyronnet, Benoit, Castel‐Lacanal, Evelyne, Roumiguie, Mathieu, Even, Lucie, Marque, Philippe, Soulié, Michel, Rischmann, Pascal, Game, Xavier
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.03.2017; Wiley
• Subjects: abobotulinum toxin; Administration, Intravesical; Adult; Botulinum toxin; Botulinum Toxins, Type A - administration & dosage; Botulinum Toxins, Type A - therapeutic use; Case-Control Studies; detrusor overactivity; Dose-Response Relationship, Drug; Female; Humans; Life Sciences; Male; Middle Aged; neurogenic bladder; Neuromuscular Agents - administration & dosage; Neuromuscular Agents - therapeutic use; onabotulinum toxin; Retrospective Studies; Success; Treatment Outcome; Urinary Bladder, Neurogenic - drug therapy; Urinary Bladder, Overactive - drug therapy; Urinary incontinence; Urodynamics - drug effects; botulinum toxin; onabotulinum toxin; neurogenic bladder; abobotulinum toxin; detrusor overactivity; Detrusor overactivity; Botulinum toxin
• ISSN: 0733-2467; 1520-6777
• DOI: 10.1002/nau.23009

Aims To compare the outcomes of the first intradetrusor injections of abobotulinum toxin 750 U and onabotulinum toxin 200 and 300 U in patients with neurogenic detrusor overactivity (NDO). Methods A retrospective case‐control study was conducted including 211 NDO patients treated in three consecutives eras with onabotulinum toxin 300 U (2004–2006; 80 patients), abobotulinum toxin 750 U (2007–2011; 78 patients) or onabotulinum toxin 200 U (2011–2014; 53 patients). Urodynamic and clinical parameters were compared between groups. The primary endpoint was the rates of success defined as the combination of urgency, urinary incontinence, and detrusor overactivity resolution. Results When comparing abobotulinum toxin to onabotulinum toxin any doses (200 or 300 U; n = 133), success rates were similar (65.4% vs. 55.6%; P = 0.16). Patients treated with abobotulinum toxin 750 U had higher success rate (65.4% vs. 41.5%; P = 0.007) compared to those who received onabotulinum toxin 200 U. In contrast, there were similar success rates in abobotulinum toxin 750 U and onabotulinum toxin 300 U groups (65.4% vs. 65%; P = 0.91) but with a trend towards longer interval between the first and the second injection in the onabotulinum toxin 300 U group (12.4 vs. 9.3 months; P = 0.09). Conclusions Intradetrusor injections of abobotulinum toxin 750 U for NDO provided better outcomes than injections of onabotulinum toxin 200 U. Success rates of abobotulinum toxin 750 U and onabotulinum toxin 300 U were similar but interval between injections tended to be longer with onabotulinum toxin 300 U. Neurourol. Urodynam. 36:734–739, 2017. © 2016 Wiley Periodicals, Inc.